Genentech receives US FDA approval on Herceptin Hylecta, a subcutaneous co-formulation using Halozyme’s recombinant Enhanze technology, for the treatment of HER2-positive metastatic breast cancer.
The new year has led to a new look to executive boards across the pharma industry, but the movement has arrived with a degree of intrigue in some cases.
Roche says it will continue to expand its biologics manufacturing capacity while reducing its small molecule network.
Pfenex expects its new Lucentis biosimilar partnership to benefit from Pfizer’s economic clout after the Hospira takeover completes.
Genentech has resolved the issues that earned its Herceptin API plant in Vacaville, California a Form 483 from the US FDA last year.
Pfizer, Roche and GSK report 2009 results
In a busy week of Big Phama results Pfizer reports sales boost from Wyeth, Roche says Genentech hit profits and GSK unveils surge in Relenza sales and plans to expand R&D restructuring.
Genentech licenses SurModics tech for SR Lucentis
Its new microparticle technology licensing deal with Genentech could be worth as much as $200m (€136m) says US delivery specialist SurModics.
Roche begins cutting jobs at Genentech
Swiss firm Roche has begun making cuts at recent $46.8bn biotech acquisition Genentech, in the first stage of a widely anticipated integration programme.
Levinson replaced as Genentech CEO by Roche employee
Art Levinson is to step down from his role as Genentech’s CEO but will play “an active role” at the company as part of Roche’s attempts to integrate and retain the biotech’s key staff.
Roche closes manufacturing site and heads out west
Roche is closing its manufacturing facility in Nutley, New Jersey and relocating its centre of commercial operations in the US to California following its $46.8bn (€36.3bn) takeover of Genentech.
Genentech to Roche: We’re equipped for hard times
Genentech believes a far-sighted approach to patent expiration, unique and life saving drugs and an unrivalled scientific culture will protect it from recession and ensure greater growth than Roche envisions.
"Anywhere, anytime" – Genentech challenges Roche
Genentech used its investor meeting to retaliate against criticisms made by Roche, saying it will debate its financial model “anywhere, anytime with anyone”.
Genentech warns board could turn hostile
As the battle for Genentech continues, the US biotech has warned its shareholders that Roche may “seek to influence our business in a manner that is contrary to our goals or strategies”.
Genentech wanted $112 per share from Roche; SEC filing
The strained relationship between Genentech and Roche has been revealed in a SEC filing, which details their differing valuations and accusations of misleading financial models.
Genentech “disappointed” at Roche’s hostile action
Roche has stepped up its pursuit of Genentech, launching a hostile bid of $42bn after growing frustrated with the lack of progress over the past six months.